Go to BioCentury homepage
Print this Print this
Welcome to BCIQ: BioCentury Online Intelligence.
Free access to this and other abridged company profiles is provided to all subscribers to SciBX: Science-Business eXchange.

Please explore the profile and if you wish to find out more about BCIQ - please Click Here

Regeneron Pharmaceuticals Inc.

Print preview Print preview

(NASDAQ:REGN)

Collapse Summary

General Information
 Location Tarrytown, N.Y.
 Region New York State
 Country U.S.
 Business Category Cancer, Ophthalmic, Inflammation
 Year Founded 1988
 Website www.regeneron.com
 Development Status Registration (03/01/2008)

Archive Items are loading
Collapse Summary

Financial Information
Total Money RaisedNumber of Completed FinancingsLast Financing DateLast Financing TypeNumber of All Financings

$639,078,000

5

11/15/2006

Follow-on

5

Financing Details (5 records)

Company NameFinancing StatusDate CompletedFinancing TypeAmount RaisedShare PricePost-Money Valuation

Regeneron Pharmaceuticals Inc.

Completed

11/15/2006

Follow-on

$175,028,000

$23.03

$1,497,706,121

Regeneron Pharmaceuticals Inc.

Completed

10/12/2001

Convert subord notes (other)

$200,000,000

 

 
More

Financial Performance Summary

1Q082Q083Q084Q081Q09

As Of Date

03/31/2008

06/30/2008

09/30/2008

12/31/2008

03/31/2009

Profit and loss

     

Sales

$0

 

$2,706,000

$3,543,000

$3,891,000

Revenues

$56,383,000

$60,653,000

$65,584,000

$55,837,000

$74,981,000

SG&A

$11,024,000

$13,465,000

$11,368,000

$13,491,000

$11,674,000

R&D

$61,270,000

$66,577,000

$73,855,000

$76,314,000

$82,146,000

Operating Income

($15,911,000)

($19,389,000)

($19,931,000)

($34,599,000)

($19,231,000)

Net Income

($11,618,000)

($18,459,000)

($21,115,000)

($31,518,000)

($17,481,000)

EPS

-$0.15

-$0.23

-$0.27

-$0.40

-$0.22

Diluted EPS

     

Shares Outstanding

78,493,000

78,689,000

78,937,000

79,190,000

79,498,000

Balance Sheet

     

Cash

$827,858,000

$744,493,000

$692,861,000

$527,461,000

$495,992,000

Valuations

     

Market Cap

$1,506,280,670

$1,136,269,160

$1,723,194,710

$1,453,928,400

$1,101,842,280

Tech Value

$678,422,670

$391,776,160

$1,030,333,710

$926,467,400

$605,850,280

R&D/Sales

     

R&D/Revenue

1.09

1.10

1.13

1.37

1.10

SG&A/Sales

  

4.20

3.81

3.00

SG&A/Revenue

0.20

0.22

0.17

0.24

0.16

Currency Rate

     

Rate

1.0000

1.0000

1.0000

1.0000

1.0000

Stocks Annual Chart

Week of 03/13/2009 - 2,676,022 Week of 03/06/2009 - 3,342,379 Week of 02/27/2009 - 3,231,468 Week of 04/03/2009 - 3,335,166 Week of 03/27/2009 - 3,046,534 Week of 03/20/2009 - 2,544,290 Week of 02/20/2009 - 1,820,453 Week of 01/23/2009 - 1,620,670 Week of 01/16/2009 - 1,410,179 Week of 01/09/2009 - 1,460,959 Week of 02/13/2009 - 2,282,485 Week of 02/06/2009 - 1,931,138 Week of 01/30/2009 - 1,805,419 Week of 06/12/2009 - 1,918,997 Week of 06/05/2009 - 2,244,238 Week of 05/29/2009 - 2,216,740 Week of 07/02/2009 - 2,010,748 Week of 06/26/2009 - 2,900,994 Week of 06/19/2009 - 3,936,672 Week of 05/22/2009 - 2,312,173 Week of 04/24/2009 - 2,318,120 Week of 04/17/2009 - 2,797,882 Week of 04/10/2009 - 2,383,387 Week of 05/15/2009 - 3,064,892 Week of 05/08/2009 - 3,270,769 Week of 05/01/2009 - 2,895,593 Week of 01/02/2009 - 348,451 Week of 09/12/2008 - 3,119,178 Week of 09/05/2008 - 4,691,697 Week of 08/29/2008 - 1,891,888 Week of 10/03/2008 - 2,724,487 Week of 09/26/2008 - 2,550,682 Week of 09/19/2008 - 5,412,560 Week of 08/22/2008 - 1,869,783 Week of 07/25/2008 - 2,875,046 Week of 07/18/2008 - 3,041,204 Week of 07/11/2008 - 2,801,424 Week of 08/15/2008 - 2,878,711 Week of 08/08/2008 - 5,283,208 Week of 08/01/2008 - 4,764,217 Week of 12/12/2008 - 2,406,552 Week of 12/05/2008 - 2,739,814 Week of 11/28/2008 - 2,031,737 Week of 12/31/2008 - 918,567 Week of 12/26/2008 - 1,091,290 Week of 12/19/2008 - 2,579,557 Week of 11/21/2008 - 3,077,183 Week of 10/24/2008 - 2,394,366 Week of 10/17/2008 - 3,008,761 Week of 10/10/2008 - 4,235,323 Week of 11/14/2008 - 2,352,566 Week of 11/07/2008 - 2,178,810 Week of 10/31/2008 - 2,978,861
Collapse Summary

Pipeline Information
Disease CategoryResearchPhase IPhase I/IIPhase IIPhase II/IIIPhase IIIRegistrationApprovedMarketed
Autoimmune

-

1

-

-

-

-

-

1

-

Cancer

-

1

-

1

-

4

-

-

-

Inflammation

-

-

-

-

-

-

-

-

1

Metabolic

-

-

-

-

-

1

-

-

-

Neurology

-

2

-

-

-

-

-

-

-

Ophthalmic

-

-

-

1

-

2

-

-

-

Total

-

4

-

2

-

7

-

1

1

Pipeline Details - Originated and out-licensed products (14 records)

Product Names

Disease Category

Standard Indication

Partners

Milestones

Latest Stage of Development

Arcalyst (Brand), IL-1 Trap (Former), rilonacept (Generic), Arcalyst (Informal)

Autoimmune

Muckle-Wells syndrome

 

 

Approved

Arcalyst (Brand), IL-1 Trap (Former), rilonacept (Generic), Arcalyst (Informal)

Inflammation

CIAS1-associated periodic syndrome (CAPS)

 

 

Marketed
More

Pipeline Details - In-licensed products

Product NamesDisease CategoryStandard IndicationIn-licensed fromMilestonesLatest Stage of DevelopmentRights

SAR164877 (Compound #)

Neurology

Pain

sanofi-aventis Group

 

Phase I

Development